The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 701–800 of 1,002
Knockdown of AURKA sensitizes the efficacy of radiation in human colorectal cancer
Liu, F., Zhang, Y., Dong, Y., Ning, P.-F., Zhang, Y., Sun, H., & Li, G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119148 · Cited by 26
Liu, H., Deng, H., Jian, Z., Cui, H., Guo, H., Fang, J. S., Zuo, Z., Deng, J., Li, Y., Wang, X., et al. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112518 · Cited by 26
Hotair promotes the migration and proliferation in ovarian cancer by miR-222-3p/CDK19 axis
Fan, L., Han, L., Lin, Y., Zhou, Z., Li, J., Wu, A., Shu, G., Roger, S., & Yin, G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04250-0 · Cited by 26
“Cyclin-dependent kinases (CDKs) are critical regulatory enzymes that drive all cell cycle transitions [34], and their activity is under stringent control to ensure successful cell division.”
BackgroundDunbar, K. L., Perlatti, B., Liu, N., Cornelius, A. R., Mummau, D., Chiang, Y., Hon, L., Nimavat, M., Pallas, J., Kordes, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310522120 · Cited by 26
Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules
Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 26
Giovanni, C. D., Novellino, E., Chilin, A., Lavecchia, A., & Marzaro, G. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1234603 · Cited by 26
“Roscovitine is in phase II clinical evaluation for the treatment of Cushing syndrome and cystic fibrosis [22].”
BackgroundInfluentialUnbalanced Growth, Senescence and Aging
Polymenis, M., & Kennedy, B. K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_8 · Cited by 26
miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1
Li, K., Zhang, J., Zhang, M., Wu, Y., Lu, X., & Zhu, Y. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02166-w · Cited by 26
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 26
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 27
Beveridge, D. J., Richardson, K. L., Epis, M. R., Brown, R. A. M., Stuart, L. M., Woo, A. J., & Leedman, P. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97190-x · Cited by 26
Kinase Inhibitor Scaffold Hopping with Deep Learning Approaches
Hu, L., Yang, Y., Zheng, S., Xu, J., Ran, T., & Chen, H. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00608 · Cited by 26
Zhou, Q., You, C., Zheng, C., Gu, Y., Gu, H., Zhang, R., Wu, H., & Sun, B. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.05.010 · Cited by 26
Kim, J., Jayne, L. A., Bai, Y., Feng, M. J. H. H., Clark, M. A., Chung, S., Christman, J. W., Cianciolo, R. E., & Pabla, N. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113939 · Cited by 26
Xia, Z.-K., Wang, W., Qiu, J.-G., Shi, X., Li, H., Chen, R., Ke, K., Dong, C., Zhu, Y., Wu, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.691769 · Cited by 25
“Palbociclib is a highly selective inhibitor of CDK4 and CDK6 kinases (Fry et al., 2004) in cells with functionally intact RB (Matsushime et al., 1992; Ewen et al., 1993; Kato et al., 1993), but not in RB absent Hep3B and BT549 (Asghar et al., 2015; Sherr et al., 2016).”
BackgroundÇetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
Fu, H., Wu, Z., Lei, Z., Teng, Q., Yang, Y., Ashby, C. R., Lei, Y., Lian, Y., & Chen, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861642 · Cited by 25
“The cyclin D-CDK4/6-RB-p16 pathway is a key regulatory pathway in the transition from G1 to S phase (Basso and Doll, 2006; Asghar et al., 2015).”
BackgroundInhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics
Yousuf, M., Shamsi, A., Mohammad, T., Azum, N., Alfaifi, S., Asiri, A. M., Elasbali, A. M., Islam, A., Hassan, M. I., & Haque, Q. M. R. (2022) · ACS Omega · doi:10.1021/acsomega.2c03479 · Cited by 25
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Mounika, P., Gurupadayya, B., Kumar, H. Y., & Bannimath, N. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230320144713 · Cited by 25
Li, Z., Xue, H., Li, J., Zheng, Z., Liu, Z., Dong, X., Wang, H., Chen, J., & Xu, S. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03007-w · Cited by 25
“The overactivation or inactivation of CDKs in tumor-related signaling pathways has been implicated in the development of cancer [35].”
BackgroundPhospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
Beck, T. N., Kaczmar, J. M., Handorf, E. A., Nikonova, A. S., Dubyk, C. W., Peri, S., Lango, M. N., Ridge, J. A., Serebriiskii, I. G., Burtness, B. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4321 · Cited by 25
“This is of particular interest as high levels of CDKN2A (p16) protein, as seen in HPV-positive SCCHN, are associated with limited response to CDK4/6 inhibition in several tumor types [25, 30, 32, 34, 35, 61].”
BackgroundInfluentialZhang, Y., Zhou, L., Leng, Y., Dai, Y., Orlowski, R. Z., & Grant, S. (2017) · Oncotarget · doi:10.18632/oncotarget.19761 · Cited by 25
“Finally, the present findings support the evaluation in bortezomibresistant MM of alternative P-TEFb antagonists, including more specific CDK9 inhibitors [47, 48], or CDK7 inhibitors, recently shown to be active in pre-clinical AML models [31].”
PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation
Zhang, H., Han, R., Ling, Z., Zhang, F., Hou, Y., You, X., Huang, M., Zhao, Z., Wang, Z., & Chen, Y. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx143 · Cited by 25
Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer
Shi, X., Li, H., Shi, A., Yao, H., Ke, K., Dong, C., Zhu, Y., Qin, Y., Ding, Y., He, Y., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6533 · Cited by 25
“Cyclin-dependent kinases (CDKs) bind to cell cycle proteins (cyclin) to form a complex, and regulate transcription, metabolism, neuro-physiological processes such as differentiation and development (3-12).”
Cyclin-dependent Kinase 7 Inhibitors in Cancer Therapy
Wang, M., Wang, T., Zhang, X., Wu, X., & Jiang, S. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0334 · Cited by 25
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-Resistant Melanoma
Li, Z., Wang, B., Gu, S. S., Jiang, P., Sahu, A. D., Chen, C.-H., Han, T., Shi, S., Wang, X., Traugh, N. C., et al. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.02.002 · Cited by 25
“Palbociclib, an FDA approved drug established to target CDK4/6, has been evaluated in (cid:1) 30 different cancer indications [48,54].”
CDK6 Is a Therapeutic Target in Myelofibrosis
Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0590 · Cited by 25
Hu, G.-S., Zheng, Z., He, Y., Wang, D.-C., Nie, R.-C., & Liu, W. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100919 · Cited by 24
“CDKs have been widely recognized for their critical role in promoting malignant behaviors in nearly all cancers (105, 106).”
He, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 24
“Unlike chemotherapy‑induced neutropenia, hematological AEs, such as neutropenia, caused by CDK4/6 inhibitors can be rapidly reversed, reflecting cytostatic effects on bone marrow neutrophil precursors (224).”
Du, Y., Yan, D., Yuan, Y., Xu, J., Wang, S., Yang, Z., Cheng, W., Tian, X., & Kan, Q. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1577665 · Cited by 24
Kumar, V., Parate, S., Thakur, G., Lee, G., Ro, H., Kim, Y., Kim, H. J., Kim, M. O., & Lee, K. W. (2021) · Biomedicines · doi:10.3390/biomedicines9091197 · Cited by 24
“Several investigations have found CDK7 inhibitors so far; however, first-generation inhibitors have shown considerable adverse effects, limiting their usage in clinical trials [71].”
BackgroundXu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 24
“CDK4/6, as a subgroup of serine/threonine kinases, promote cell cycle regulation by phosphorylating retinoblastoma (Rb) protein after interacting with cyclin D and then initiate the cell cycle transition from G1 phase to S phase (6).”
BackgroundDennis, M. J., Sacco, A. G., Qi, Y., Bykowski, J., Pittman, E. I., Chen, R., Messer, K. S., Cohen, E. E. W., & Gold, K. A. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.106219 · Cited by 24
Emerging approaches to CDK inhibitor development, a structural perspective
Hope, I., Endicott, J., & Watt, J. E. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00201a · Cited by 24
Wang, H., Tian, R.-F., Liang, X., Fan, J., Duan, Z.-C., Fan, X.-Y., Zhang, J., Yao, D.-S., Chen, Z., & Li, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015042 · Cited by 25
“CDK1 is a member of the Ser/Thr protein kinase family, which plays a key role in controlling the eukaryotic cell cycle by regulating the centrosome cycle and mitotic initiation (41, 42).”
BackgroundPandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 24
“A growing number of malignancies are being treated with CDK inhibition because it stops cell proliferation [12,13] The discovery of “key regulators of the cell cycle” made by Leland H.”
BackgroundSolanki, P. M., Rana, N., Jha, P. C., & Manhas, A. (2023) · Biocell · doi:10.32604/biocell.2023.026615 · Cited by 24
Sayed, E. M., Bakhite, E. A.-G., Hassanien, R., Farhan, N., Aly, H. F., Morsy, S. G., & Hassan, N. A. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01139-w · Cited by 24
“The data was analysied and plot by Graphpad prism software [42, 43].”
MethodDing, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.052 · Cited by 24
Coin, F., & Egly, J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.08.006 · Cited by 24
“These kinases are bona fide targets of antitumor drugs, and many CDK inhibitors have been discovered in recent years (Asghar et al., 2015).”
BackgroundTraditional Ayurvedic medicines: Pathway to develop anti-cancer drugs
Bhandariab, M., & Sc, A. R. (2015) · Journal of Molecular Pharmaceutics & Organic Process Research · doi:10.4172/2329-9053.1000130 · Cited by 24
“Despite its potent in vitro activities and extensive investment in these trials, there are no Phase III studies reported [38] to date.”
BackgroundTargeting kinase signaling pathways with constrained peptide scaffolds
Hanold, L. E., Fulton, M. D., & Kennedy, E. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.014 · Cited by 24
Zhao, Y., Wang, P., Chen, S., Han, C., Yan, Q., Zheng, L. T., Jia, J., Ren, Z., & Zhen, X. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.03.034 · Cited by 26
Targeting Cyclin-Dependent Kinases in Ovarian Cancer
Zhou, Q. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1283508 · Cited by 24
Chang, J.-W., Ding, Y., Qamar, M. T. U., Shen, Y., Gao, J., & Chen, L. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz044 · Cited by 24
Wang, J., Zhang, Y., Lu, L., Lu, Y., Tang, Q., & Pu, J. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29197 · Cited by 24
CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma
Ran, Q., Jin, F., Xiang, Y., Xiang, L., Wang, Q., Li, F., Chen, L., Zhang, Y., Wu, C. T., Zhou, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906578116 · Cited by 24
“Numerous CDK-inhibiting drugs have been developed as potential cancer therapeutics and evaluated in a wide variety of cancer types, but only a few CDK2 inhibitors entered clinical trials due to their low selectivity in discriminating between cancerous and normal cells (36).”
BackgroundRecent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy
Liang, H., Du, J., Elhassan, R. M., Hou, X., & Fang, H. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850693 · Cited by 24
Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.03.006 · Cited by 23
Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
Umfress, A., Singh, S., Ryan, K. J., Chakraborti, A., Plattner, F., Sonawane, Y. A., Mallareddy, J. R., Acosta, E. P., Natarajan, A., & Bibb, J. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863762 · Cited by 23
“Numerous CDK inhibitors have been developed for the treatment of various cancer types (Asghar et al., 2015; Mangini et al., 2015; Syed, 2017).”
BackgroundDong, H.-Q., Liang, S.-J., Xu, Y., Dai, Y., Sun, N., Deng, D., & Cheng, P. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5409 · Cited by 23
“in uncontrolled cell proliferation (60), and unscheduled cell division is a hallmark of malignant tumors.”
BackgroundChang, H., Wang, Q., Meng, X., Chen, X., Deng, Y., Li, L., Yang, Y., Song, G., & Jia, H. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00402 · Cited by 23
Barakat, A., Alshahrani, S., Al‐Majid, A. M., Alamary, A. S., Haukka, M., Abu-Serie, M. M., Domingo, L. R., Ashraf, S., Ul‐Haq, Z., Nafie, M. S., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2281260 · Cited by 23
“However, few inhibitors reached clinical studies as anticancer agents of which some have been discontinued due to the associated side effects (e.g. AZD5438, SNS-032 and R547) or failure to achieve the acceptable clinical outcome (e.g. AG-024322) 16,17 .”
BackgroundNicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 24
“While preclinical studies demonstrated the efficacy of CDK4/6 inhibition in Rb-proficient human tumor xenograft models, the introduction of CDK4/6 inhibitors has significantly changed the management of endocrine-resistant ER+ breast cancer [85].”
BackgroundLiu, Y., Li, Z., Zhang, J., Liu, W., Guan, S., Zhan, Y., Fang, Y., Li, Y., Deng, H., & Shen, Z. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02719-2 · Cited by 23
“However the clinical curative effect is often suboptimal, implying that selection of potential patients that respond to cell cycle inhibition and developing more ef fi cient drug combinational approaches is of critical importance [19, 21, 22].”
Song, L., Niu, Y., Chen, R., Ju, H., Liu, Z., Zhang, B., Xie, W., & Gao, Y. (2024) · Marine Drugs · doi:10.3390/md22070316 · Cited by 23
“The seaweed samples were washed with distilled water, dried in a drying oven at 80 ◦ C for 12 h, ground into powder using a grinder with a 100-mesh sieve, and then sealed in bags for use.”
MethodTeotia, V., Jha, P. K., & Chopra, M. (2024) · ACS Omega · doi:10.1021/acsomega.4c05414 · Cited by 23
“34 To this effect, three CDK4/6 selective inhibitors, Palbociclib, Ribociclib, and Abemaciclib, 35 have been approved by the U.S. FDA for use in breast cancer therapies.”
BackgroundPetrossian, K., Kanaya, N., Lo, C., Hsu, P.-Y., Nguyen, D. M., Yang, L., Yang, L., Warden, C., Wu, X., Pillai, R. K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25552 · Cited by 23
“Many cancers display dysregulation of cell cycle networks [16], and the ER-cyclin D1-CDK4/6-RB pathway is critical for the estrogen action on the cell cycle in ER+ breast cancer [8, 9, 17–19].”
BackgroundA new small cell lung cancer biomarker identified by Cell-SELEX generated aptamers
Zhou, W., Zhao, L., Yuan, H., Xu, L., Tan, W., Song, Y., & Fang, X. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.06.023 · Cited by 23
A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments
Lagarde, N., Goldwaser, E., Pencheva, T., Jereva, D., Pajeva, I. K., Rey, J., Tufféry, P., Villoutreix, B. O., & Miteva, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184648 · Cited by 23
“CDK2 is a cyclin-dependent kinase involved in cell replication and tumor growth, and it is a promising cancer target [42].”
BackgroundWang, X., Deng, K., Wang, C., Li, Y., Wang, T., Huang, Z. L., Ma, Y., Sun, P., Shi, Y., Yang, S., et al. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1705290 · Cited by 23
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., Ross, E. A., & El‐Deiry, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00150-8 · Cited by 24
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
“Cyclin-dependent kinases (CDKs) are important regulators of cell division [1].”
BackgroundCDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 23
“Pan-CDK inhibitors were first developed over three decades ago, but their therapeutic potential was thwarted by severe toxicities, and now more specific inhibitors have mostly replaced these early pan-CDK inhibitors (18).”
BackgroundPsarra, V., Fousteris, M. A., Hennig, L., Bantzi, M., Giannis, A., & Nikolaropoulos, S. S. (2016) · Tetrahedron · doi:10.1016/j.tet.2016.03.048 · Cited by 23
Discovery of novel CDK inhibitors via scaffold hopping from CAN508
Jing, L., Tang, Y., & Xiao, Z. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.02.054 · Cited by 23
Wang, H., Liu, H., Min, S., Shen, Y., Li, W., Chen, Y., & Wang, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.080 · Cited by 23
Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders
Zhuang, Z., Byun, W. S., Kozicka, Z., Donovan, K. A., Dwyer, B. G., Thornhill, A. M., Jones, H. M., Jiang, Z., Zhu, X., Fischer, E. S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202508427 · Cited by 23
Jurić, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaïh, A., Lamfers, M. L. M., Hopkins, A. M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04050-7 · Cited by 22
Shen, Z., Wang, J., Ke, K., Chen, R., Zuo, A., Zhang, R., Wan, W., Xie, X., Li, X., Song, N., et al. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1991121 · Cited by 22
“CDK4/6 and CDK2 are the dominant CDKs con-trol cell G1/S transition though finely regulation of cancer suppressor Rb protein phosphorylation and subsequently releasing of E2F, a transcriptional factor in the cell cycle regulation [20,21].”
BackgroundRetractedEmerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
Rekha, T. N., & Shin, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065190 · Cited by 22
“Cyclin-dependent kinases regulate eukaryotic cell division, proliferation, and gene expression [68].”
BackgroundHummel, J. R., Xiao, K., Yang, J. C., Epling, L. B., Mukai, K., Ye, Q., Xu, M., Qian, D., Huo, L., Weber, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02287 · Cited by 22
Yang, X., Hu, X., Yin, J., Li, W., Fu, Y., Yang, B., Fan, J., Lu, F., Qin, T., Kang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46358-w · Cited by 22
“CDK1 controls critical cell cycle events, such as DNA replication and G2/M-phase transition 34,35 .”
Rye, C. S., Chessum, N. E. A., Lamont, S. G., Pike, K. G., Faulder, P., Demeritt, J., Kemmitt, P. D., Tucker, J. A., Zani, L., Cheeseman, M. D., et al. (2016) · MedChemComm · doi:10.1039/c6md00159a · Cited by 22
Lü, F., Luo, G., Qiao, L., Jiang, L., Li, G., & Zhang, Y. (2016) · Molecules · doi:10.3390/molecules21091259 · Cited by 22
Emerging cell cycle inhibitors for acute myeloid leukemia
Zahr, A. A., & Borthakur, G. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1330885 · Cited by 22
“Targeting transcriptional CDKs such as CDK8/CDK7/ CDK9 These CDKs are primarily transcriptional kinases [81].”
BackgroundKabir, M. F., Ali, J. M., & Hashim, O. H. (2018) · PeerJ · doi:10.7717/peerj.5203 · Cited by 22
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
Kinoshita, S., Ishida, T., Ito, A., Narita, T., Masaki, A., Suzuki, S., Yoshida, T., Ri, M., Kusumoto, S., Komatsu, H., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191395 · Cited by 22
“The latter may have been due to their insufficient selectivity for CDK9.(48) In contrast, BAY 1143572 exhibits marked selectivity for CDK9/PTEFb,21 and possesses strong antitumor effects against NK-cell leukemia/lymphoma including ANKL, not only in vitro, but also in animal models in vivo.”
BackgroundSynthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy
Rana, S., Sonawane, Y. A., Taylor, M., Kizhake, S., Zahid, M., & Natarajan, A. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.020 · Cited by 22
Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer
Zhang, S., Guan, Y., Liu, X., Ju, M., & Zhang, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.175 · Cited by 22
Yang, J., Lan, J., Du, H., Zhang, X., Li, A., Zhang, X., Liu, Y., Zhang, J., Zhang, C., Ding, Y., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.12.026 · Cited by 22
Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma
Shao, Y., Li, Y.-S., Hsu, H.-W., Lin, H., Wang, H., Wo, R. R., Cheng, A., & Hsu, C. (2019) · Cancers · doi:10.3390/cancers11101433 · Cited by 22
“CDKs constitute a family of protein kinases involved in regulating cell cycle progression and other cell-cycle-independent functions such as transcription, mRNA processing, and nerve cell differentiation [17,18].”
BackgroundSynthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
Deneka, A. Y., Einarson, M. B., Bennett, J. M., Nikonova, A. S., Elmekawy, M., Zhou, Y., Lee, J. W., Burtness, B. A., & Golemis, E. A. (2020) · Cancers · doi:10.3390/cancers12020306 · Cited by 22
“While inhibitors of these proteins have some clinical activity, single-agent potency is often limited in solid tumors and associated with cytostatic rather than cytotoxic effects [20].”
BackgroundTargeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 22
One drug to treat many diseases: unlocking the economic trap of rare diseases
Pierzynowska, K., Kamińska, T., & Węgrzyn, G. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00617-z · Cited by 22
“Some of them can be used in breast cancer therapy (Asghar et al. 2015).”
BackgroundLü, S., Sun, C., Chen, H., Zhang, C., Li, W., Wu, L.-H., Zhu, J., Sun, F., Huang, J., Wang, J., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s265779 · Cited by 22
Yuan, K., Ji, M., Xie, S., Qiu, Z., Chen, W., Min, W., Xia, F., Zheng, M., Wang, X., Li, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02019 · Cited by 22
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Laha, D., Grant, R., Mishra, P., Boufraqech, M., Shen, M., Zhang, Y., Hall, M. D., Quezado, M., Melo, M. S. D., Rivero, J. D., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02464-5 · Cited by 22
“CDK2 and A- and E-type cyclins form active kinase complexes to phosphorylate proteins involved in DNA replication, which are inactivated by the cell cycle checkpoints p21Cip1 and p27Kip1 [29].”
BackgroundDo CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu, N. N., & Johnson, F. M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1274731 · Cited by 24
“low specificity, and adverse effects [52,53].”
Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics
Lang, F., Kaur, K., Zaheer, J., Ribeiro, D. L., & Yang, C. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3571 · Cited by 21
Wang, H., Liao, P., Zeng, S. X., & Lu, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685289 · Cited by 21
“Fortunately, several CDK4 inhibitors have been developed into attractive therapeutic options.(23) These selective CDK4/6 inhibitors include palbociclib (PD0332991, PD), abemaciclib (LY2835219), and ribociclib (LEE011).”
BackgroundCrystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964
Kelso, S., O’Brien, S., Kurinov, I. V., Angers, S., & Sicheri, F. (2022) · Structure · doi:10.1016/j.str.2022.10.003 · Cited by 21
Chen, W., Ji, M., Cheng, H., Zheng, M., Xia, F., Min, W., Yang, H., Wang, X., Wang, L., Cao, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00947 · Cited by 21
Wang, Q., Zhang, W. Y., Yin, D., Tang, Z., Zhang, E., & Wu, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01276-y · Cited by 21
“CKIs are a class of genes that encode proteins that bind to and inactivate CCN/CDK complexes, which serve as suppressors in tumor progression [40, 41].”
BackgroundDifferent Synthetic Methods for the Preparation of Triazolopyrimidines and their Biological Profile
Hibot, A., Oumessaoud, A., Hafid, A., Khouili, M., & Pujol, M. D. (2023) · ChemistrySelect · doi:10.1002/slct.202301654 · Cited by 21
Lo, Y.-C., & Lin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102429 · Cited by 21
“The potential use of PBC in other cancer therapies is under wide investigation due to dysregulated cyclin D-CDK4/6-Rb pathway occurring in many types of tumors [5,6].”
BackgroundProfile of palbociclib in the treatment of metastatic breast cancer
Elbaz, M., & Ehab, M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s83146 · Cited by 22
“43,44 However, due to their low therapeutic index, low sensitivity, and multitargets, first-generation CDK inhibitors have been discontinued.”
Zhou, M., Lin, F., Xu, W., Jin, R., & Xu, A. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9299 · Cited by 21
“CDKs are major components involved in cell cycle progression (20,21).”
Hu, X., Zhao, H., Wang, Y., Liu, Z., Feng, B., & Tang, C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.08.035 · Cited by 21
Liu, Y., Zhao, R., Fang, S., Li, Q., Jin, Y., & Liu, B. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12574 · Cited by 21
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.